Paper Details

  1. Home
  2. Paper Details

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.

Author: Al-SawafOthman, BöttcherSebastian, ChingTravers, ChylaBrenda, EichhorstBarbara, FinkAnna-Maria, FischerKirsten, HallekMichael, JiangYanwen, KreuzerKarl-Anton, LiaoMichael Z, LuTong, MilesDale, PanchalAnesh, RitgenMatthias, RobrechtSandra, SchneiderChristof, StilgenbauerStephan, TandonManeesh, TauschEugen, WendtnerClemens-Martin, ZhangCan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Venetoclax and obinutuzumab (Ven-Obi) treatment for previously untreated chronic lymphocytic leukemia (CLL) resulted in high rates of minimal residual disease (MRD) negativity and long-term disease control.
Paper Details　
Original Abstract of the Article :
The CLL14 study has established one-year fixed-duration treatment of venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic lymphocytic leukemia. With all patients off treatment for at least three years, we report a detailed analysis of minimal residual disease (MRD) ki...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678026/

データ提供：米国国立医学図書館（NLM）

Long-Term Outcomes of Venetoclax-Obinutuzumab Treatment in Chronic Lymphocytic Leukemia (CLL)

In the fight against cancer, researchers constantly strive to develop more effective and durable treatments. This study examines the long-term outcomes of venetoclax-obinutuzumab (Ven-Obi) treatment in patients with previously untreated chronic lymphocytic leukemia (CLL). The authors conducted a detailed analysis of minimal residual disease (MRD) kinetics and long-term outcomes of patients treated in the CLL14 study, providing valuable insights into the durability of this treatment regimen.

Ven-Obi Shows Promise for Durable Remission

The study found that Ven-Obi treatment led to deep and durable remissions in CLL patients, with a significant proportion achieving MRD negativity. The authors noted that long-term follow-up data showed sustained MRD negativity in a considerable number of patients, suggesting a potential for durable remission. This study offers promising evidence for the effectiveness of Ven-Obi treatment in CLL, potentially leading to longer periods of remission and improved quality of life for patients.

Hope for CLL Patients

This study provides a glimmer of hope for individuals battling CLL, showcasing the potential for durable remissions with Ven-Obi treatment. The findings underscore the need for continued research to further explore the long-term efficacy of this treatment regimen and identify potential strategies for optimizing outcomes. It's like finding a hidden oasis of hope in the vast desert of CLL, offering a path to longer periods of remission and improved quality of life.

Dr. Camel's Conclusion

This study offers a beacon of hope for CLL patients, demonstrating the potential of Ven-Obi treatment to induce deep and durable remissions. The findings underscore the need for further research to refine our understanding of this treatment regimen and to explore strategies for maximizing its effectiveness. It's like finding a hidden oasis of hope in the vast desert of CLL, offering a path to longer periods of remission and improved quality of life.
Date :
  1. Date Completed 2022-02-07
  2. Date Revised 2022-12-21
Further Info :

Pubmed ID

34709929

DOI: Digital Object Identifier

PMC8678026

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.